The specific targets of miR-188-3p have been identified as NOD-like receptors 3 (NLRP3) and cyclin-dependent kinase 5 (Cdk5), signifying its promising potential as a therapeutic target in Parkinson’s disease (PD) [77]. Here, CDK5 is linked to Parkinson disease.